Relapsed multiple myeloma: choosing the next treatment

Find out what has changed

Relapse may first appear as rising protein or free light-chain measurements, or it may cause new symptoms and organ problems. The team considers the size and speed of the change, imaging, marrow findings when needed and any effect on kidneys, bones or blood counts.

Ask whether the current finding calls for closer monitoring, further assessment or treatment now. A laboratory trend over several visits is often more informative than a single result. Report new pain, weakness, increasing thirst, reduced urine output or other changes rather than waiting for the next scheduled blood test.

Sources and references: [1] [2]

Identify what the myeloma is resistant to

The next choice depends on the medicines already used and whether the disease progressed during them or after a response. The terms relapsed and refractory describe different patterns. A medicine stopped for side effects may have a different role from one the cancer was growing through.

Prepare a dated list of regimens, maintenance, transplant and any cellular therapy. Include the best response, its duration and the reason each treatment ended. This helps the specialist distinguish options that remain useful from combinations unlikely to add much because of established resistance.

Sources and references: [1]

Some relapses need action before travel

Rapid kidney deterioration, severe bone problems, spinal cord symptoms or a quickly growing mass can require urgent treatment. The team may need to control the disease and stabilize complications before another procedure or an overseas transfer is practical.

Seek emergency assessment for new leg weakness, numbness around the groin or changes in bladder or bowel control with back pain. If the relapse is slower and you feel well, there may be time for a focused second opinion. Ask the current hematologist how much time is available and which steps can happen in parallel.

Sources and references: [1] [2]

Compare the combinations that still fit

Relapse regimens may include anti-CD38 antibodies, proteasome inhibitors, immunomodulatory medicines, steroids and other drugs, chosen according to prior exposure and tolerance. Newer options can change the comparison. In August 2026, the FDA granted accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone after at least one prior line including a proteasome inhibitor and an immunomodulatory agent.

Other choices have different monitoring needs. The US-approved belantamab mafodotin combination, for example, requires particular attention to eye toxicity. For Shanghai care, ask the center to confirm the current Chinese indication and practical access for each named regimen under discussion.

Sources and references: [1] [3] [4]

Consider CAR-T and bispecific timing early

CAR-T and bispecific antibodies are important options in defined relapse settings. They have different product requirements, targets and schedules. CAR-T needs cell collection and manufacturing; a bispecific antibody can be supplied without individual manufacturing, though assessment and monitored first dosing still need planning.

Some options are available earlier in the treatment sequence than older descriptions suggest. Ask when referral should happen, whether bridging treatment is needed and how previous BCMA-directed therapy affects the next choice. Include the full course of care, from preparation through infection protection and follow-up, in the comparison.

Sources and references: [5] [6] [7] [1]

Review transplant and clinical trials where relevant

A further autologous transplant may be discussed for selected patients, considering earlier transplant response, the length of remission, fitness and other available treatments. The expected benefit should be compared with the alternatives at this relapse, rather than treated as an automatic repeat of the first plan.

A clinical trial may also offer a relevant option based on the disease and prior medicines. Ask for the study identifier, current screening status and main eligibility criteria. Clarify what happens if you do not qualify and whether another treatment is needed while the assessment takes place.

Sources and references: [1] [8]

Make supportive care part of the next regimen

Previous treatment may have left nerve pain, fatigue, infections or other problems that influence what is tolerable now. Tell the team which side effect most affects daily life. It may be possible to adjust the medicine, dose, schedule or supportive treatment while still addressing the myeloma.

Review bone protection, pain control, kidney care, clot prevention and infection prevention as appropriate to the regimen. Ask what blood tests or specialist visits are needed and who reviews them. A manageable follow-up plan is particularly important when treatment is shared between a specialist center and a local hospital.

Sources and references: [1]

Prepare a relapse review that answers the next decision

EastMedGo can help organize a Shanghai second-opinion request or a CAR-T eligibility assessment, depending on the question. Begin with the treatment timeline, recent laboratory trends, imaging and any new symptoms.

When you contact us, explain whether you need a comparison before starting the next regimen, an assessment of cellular therapy or advice on records needed for a trial review. We can coordinate document preparation and appointment logistics, then help clarify the expected local stay and follow-up arrangements after the clinical team has reviewed the case.

Common questions